Moleculin Completes Enrollment in R/R AML Trial
Moleculin Biotech announced it has finalized enrollment in the Part A of its Phase 2/3 MIRACLE trial for Annamycin. This achievement positions the company to report pivotal efficacy data on the treatment for relapsed or refractory acute myeloid leukemia in Q1 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed